Your browser doesn't support javascript.
loading
HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry.
Paoletti, Audrey; Allouch, Awatef; Caillet, Marina; Saïdi, Hela; Subra, Frédéric; Nardacci, Roberta; Wu, Qiuji; Muradova, Zeinaf; Voisin, Laurent; Raza, Syed Qasim; Law, Frédéric; Thoreau, Maxime; Dakhli, Haithem; Delelis, Olivier; Poirier-Beaudouin, Béatrice; Dereuddre-Bosquet, Nathalie; Le Grand, Roger; Lambotte, Olivier; Saez-Cirion, Asier; Pancino, Gianfranco; Ojcius, David M; Solary, Eric; Deutsch, Eric; Piacentini, Mauro; Gougeon, Marie-Lise; Kroemer, Guido; Perfettini, Jean-Luc.
Afiliação
  • Paoletti A; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Allouch A; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Caillet M; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France; INSERM U848, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France.
  • Saïdi H; Institut Pasteur, Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, 25 rue du Dr. Roux, F-75015 Paris, France.
  • Subra F; CNRS UMR 8113 LBPA, Ecole Normale Supérieure de Cachan, 61 avenue du Président Wilson, F-94230 Cachan, France.
  • Nardacci R; National Institute for Infectious Diseases "Lazzaro Spallanzani,", Via Portuense 292, 00149 Rome, Italy.
  • Wu Q; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Muradova Z; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Voisin L; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Raza SQ; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Law F; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Thoreau M; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Dakhli H; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
  • Delelis O; CNRS UMR 8113 LBPA, Ecole Normale Supérieure de Cachan, 61 avenue du Président Wilson, F-94230 Cachan, France.
  • Poirier-Beaudouin B; Institut Pasteur, Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, 25 rue du Dr. Roux, F-75015 Paris, France.
  • Dereuddre-Bosquet N; INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Fontenay-aux-Roses, France; Université Paris Sud, UMR 1184, Fontenay-aux-Roses, France; CEA, DSV/iMETI, Division of Immunology-Virology, IDMIT, Fontenay-aux-Roses, France.
  • Le Grand R; INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Fontenay-aux-Roses, France; Université Paris Sud, UMR 1184, Fontenay-aux-Roses, France; CEA, DSV/iMETI, Division of Immunology-Virology, IDMIT, Fontenay-aux-Roses, France.
  • Lambotte O; INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Fontenay-aux-Roses, France; CEA, DSV/iMETI, Division of Immunology-Virology, IDMIT, Fontenay-aux-Roses, France; APHP, Service de Médecine Interne - Immunologie Clinique, Hôpitaux Universitaires Paris Sud, F-94270 Le Kre
  • Saez-Cirion A; Unité HIV, Inflammation et Persistance, Institut Pasteur, 25 rue du Dr. Roux, F-75025 Paris, France.
  • Pancino G; Unité HIV, Inflammation et Persistance, Institut Pasteur, 25 rue du Dr. Roux, F-75025 Paris, France.
  • Ojcius DM; Department of Biomedical Sciences, University of the Pacific, Arthur A. Dugoni School of Dentistry, 155 Fifth Street, San Francisco, CA 94103, USA; Université Paris Diderot, Sorbonne Paris Cité, 75013 Paris, France.
  • Solary E; INSERM U1009, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France.
  • Deutsch E; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.
  • Piacentini M; National Institute for Infectious Diseases "Lazzaro Spallanzani,", Via Portuense 292, 00149 Rome, Italy; Department of Biology, University of Rome "Tor Vergata,", Via della Ricerca Scientifica 1, 00133 Rome, Italy.
  • Gougeon ML; Institut Pasteur, Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, 25 rue du Dr. Roux, F-75015 Paris, France.
  • Kroemer G; INSERM U848, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Metabolomics Platform, Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, France; Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Paris, France; Université Paris Descart
  • Perfettini JL; Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Par
Cell Rep ; 28(13): 3381-3394.e7, 2019 09 24.
Article em En | MEDLINE | ID: mdl-31553908
ABSTRACT
Purinergic receptors and nucleotide-binding domain leucine-rich repeat containing (NLR) proteins have been shown to control viral infection. Here, we show that the NLR family member NLRP3 and the purinergic receptor P2Y2 constitutively interact and regulate susceptibility to HIV-1 infection. We found that NLRP3 acts as an inhibitory factor of viral entry that represses F-actin remodeling. The binding of the HIV-1 envelope to its host cell receptors (CD4, CXCR4, and/or CCR5) overcomes this restriction by stimulating P2Y2. Once activated, P2Y2 enhances its interaction with NLRP3 and stimulates the recruitment of the E3 ubiquitin ligase CBL to NLRP3, ultimately leading to NLRP3 degradation. NLRP3 degradation is permissive for PYK2 phosphorylation (PYK2Y402∗) and subsequent F-actin polymerization, which is required for the entry of HIV-1 into host cells. Taken together, our results uncover a mechanism by which HIV-1 overcomes NLRP3 restriction that appears essential for the accomplishment of the early steps of HIV-1 entry.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Actinas / HIV-1 / Proteína 3 que Contém Domínio de Pirina da Família NLR Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Actinas / HIV-1 / Proteína 3 que Contém Domínio de Pirina da Família NLR Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2019 Tipo de documento: Article